Cargando…

Effect of the sphingosine-1-phosphate receptor modulator ozanimod on leukocyte subtypes in relapsing MS

OBJECTIVE: To better understand ozanimod's mechanism of action (MOA), we conducted exploratory analyses from a phase 1 study to characterize ozanimod's effect on circulating leukocyte subsets in patients with relapsing multiple sclerosis. METHODS: An open-label pharmacodynamic study random...

Descripción completa

Detalles Bibliográficos
Autores principales:	Harris, Sarah, Tran, Jonathan Q., Southworth, Harry, Spencer, Collin M., Cree, Bruce A.C., Zamvil, Scott S.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2020
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7413711/ https://www.ncbi.nlm.nih.gov/pubmed/32737072 http://dx.doi.org/10.1212/NXI.0000000000000839

Ejemplares similares

Competitive Binding of Ozanimod and Other Sphingosine 1-Phosphate Receptor Modulators at Receptor Subtypes 1 and 5
por: Selkirk, Julie V., et al.
Publicado: (2022)

Effects of High‐ and Low‐Fat Meals on the Pharmacokinetics of Ozanimod, a Novel Sphingosine‐1‐Phosphate Receptor Modulator
por: Tran, Jonathan Q., et al.
Publicado: (2017)

Results From the First‐in‐Human Study With Ozanimod, a Novel, Selective Sphingosine‐1‐Phosphate Receptor Modulator
por: Tran, Jonathan Q., et al.
Publicado: (2017)

Plasma neurofilament light chain concentrations as a biomarker of clinical and radiologic outcomes in relapsing multiple sclerosis: Post hoc analysis of Phase 3 ozanimod trials
por: Harris, Sarah, et al.
Publicado: (2021)

Cardiac Safety of Ozanimod, a Novel Sphingosine‐1‐Phosphate Receptor Modulator: Results of a Thorough QT/QTc Study
por: Tran, Jonathan Q., et al.
Publicado: (2017)

SARS‐CoV‐2 vaccination and infection in ozanimod‐treated participants with relapsing multiple sclerosis
por: Cree, Bruce A. C., et al.
Publicado: (2023)

"Hit smart and early" - MS-Therapie mit Ozanimod
por: Ottenjann, Henrike
Publicado: (2023)

An Overview of the Efficacy and Safety of Ozanimod for the Treatment of Relapsing Multiple Sclerosis
por: Fronza, Marzia, et al.
Publicado: (2021)

Ozanimod for multiple sclerosis
Publicado: (2021)

Long-term safety and efficacy of ozanimod in relapsing multiple sclerosis: Up to 5 years of follow-up in the DAYBREAK open-label extension trial
por: Cree, Bruce AC, et al.
Publicado: (2022)

Concentration‐QTc Modeling of Ozanimod’s Major Active Metabolites in Adult Healthy Subjects
por: Briggs, Emily, et al.
Publicado: (2021)

Efficacy and safety of ozanimod in multiple sclerosis: Dose-blinded extension of a randomized phase II study
por: Cohen, Jeffrey A, et al.
Publicado: (2018)

Acute liver injury in a Glatopa-treated patient with MS
por: Sabatino, Joseph J., et al.
Publicado: (2017)

Ozanimod: A Review in Ulcerative Colitis
por: Paik, Julia
Publicado: (2022)

"Hit smart and early" mit Ozanimod
por: Ottenjann, Henrike
Publicado: (2023)

MOG transmembrane and cytoplasmic domains contain highly stimulatory T-cell epitopes in MS
por: Varrin-Doyer, Michel, et al.
Publicado: (2014)

Longitudinal adaptive immune responses following sequential SARS-CoV-2 vaccinations in MS patients on anti-CD20 therapies and sphingosine-1-phosphate receptor modulators
por: Sabatino, Joseph J., et al.
Publicado: (2023)

Reduction of CD8(+) T lymphocytes in multiple sclerosis patients treated with dimethyl fumarate
por: Spencer, Collin M., et al.
Publicado: (2015)

Correction to: Ozanimod: A Review in Ulcerative Colitis
por: Paik, Julia
Publicado: (2022)

Neuroprotection by Ozanimod Following Intracerebral Hemorrhage in Mice
por: Wang, Fei, et al.
Publicado: (2022)

Interaction of microRNAs with sphingosine kinases, sphingosine-1 phosphate, and sphingosine-1 phosphate receptors in cancer
por: Xu, Guangmeng, et al.
Publicado: (2021)

Su1480: TREATMENT-EMERGENT COVID-19 INFECTIONS IN OZANIMOD ULCERATIVE COLITIS AND MULTIPLE SCLEROSIS CLINICAL TRIALS
por: Ungaro, Ryan C., et al.
Publicado: (2022)

Cost Per Relapse Avoided for Ozanimod Versus Other Selected Disease-Modifying Therapies for Relapsing–Remitting Multiple Sclerosis in the United States
por: Kantor, Daniel, et al.
Publicado: (2023)

Sphingosine-1-phosphate receptor 3 promotes leukocyte rolling by mobilizing endothelial P-selectin
por: Nussbaum, Claudia, et al.
Publicado: (2015)

Decreased Expression of Sphingosine-1-Phosphate Receptor 1 in the Blood Leukocyte of Rheumatoid Arthritis Patients
por: Choi, Hyun Suk, et al.
Publicado: (2018)

Ozanimod to Treat Relapsing Forms of Multiple Sclerosis: A Comprehensive Review of Disease, Drug Efficacy and Side Effects
por: Lassiter, Grace, et al.
Publicado: (2020)

The Role of Sphingolipids and Sphingosine-1-phosphate—Sphingosine-1-phosphate-receptor Signaling in Psoriasis
por: Masuda-Kuroki, Kana, et al.
Publicado: (2023)

The Gut Microbiome in Neuromyelitis Optica
por: Zamvil, Scott S., et al.
Publicado: (2017)

An update on the use of sphingosine 1-phosphate receptor modulators for the treatment of relapsing multiple sclerosis
por: Dumitrescu, Laura, et al.
Publicado: (2023)

Plasma Sphingosine-1-Phosphate Is Elevated in Obesity
por: Kowalski, Greg M., et al.
Publicado: (2013)

Multiple-Dose Pharmacokinetics of Ozanimod and its Major Active Metabolites and the Pharmacodynamic and Pharmacokinetic Interactions with Pseudoephedrine, a Sympathomimetic Agent, in Healthy Subjects
por: Tran, Jonathan Q., et al.
Publicado: (2020)

Modulating sphingosine 1-phosphate receptor signaling skews intrahepatic leukocytes and attenuates murine nonalcoholic steatohepatitis
por: Liao, Chieh-Yu, et al.
Publicado: (2023)

Sphingosine 1-Phosphate and Atherosclerosis
por: Kurano, Makoto, et al.
Publicado: (2018)

Ozanimod for Treatment of Relapsing-Remitting Multiple Sclerosis in Adults: A Systematic Review and Meta-Analysis of Randomized Controlled Trials
por: Sun, Yue, et al.
Publicado: (2020)

Comparative Efficacy and Safety of Ozanimod and Dimethyl Fumarate for Relapsing-Remitting Multiple Sclerosis Using Matching-Adjusted Indirect Comparison
por: Cohan, Stanley, et al.
Publicado: (2021)

Sphingosine Kinase 1 and Sphingosine-1-Phosphate Signaling in Colorectal Cancer
por: Bao, Yonghua, et al.
Publicado: (2017)

Mechanism of sphingosine 1-phosphate clearance from blood
por: Kharel, Yugesh, et al.
Publicado: (2020)

Reduced sphingosine kinase-1 and enhanced sphingosine 1-phosphate lyase expression demonstrate deregulated sphingosine 1-phosphate signaling in Alzheimer’s disease
por: Ceccom, Johnatan, et al.
Publicado: (2014)

Validated LC‐MS/MS method of Sphingosine 1‐phosphate quantification in human serum for evaluation of response to radiotherapy in lung cancer
por: Tang, Xiaohui, et al.
Publicado: (2020)

Benefit–Risk Profile of Sphingosine-1-Phosphate Receptor Modulators in Relapsing and Secondary Progressive Multiple Sclerosis
por: Comi, Giancarlo, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_mefb09ke0570018a4ade25o511